|
Unit:
|
Xiuyu District People's Government of Putian City, Fujian Province
|
|
|
Project Area:
|
putian Xiuyu District
|
|
|
Industry:
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode:
|
Individual Proprietorship,Joint Venture,Collaborate
|
|
|
Nature of Project:
|
Permit
|
|
|
Working Progress in Prior Period:
|
Among them, the biopharmaceutical raw material production base project is expected to be jointly constructed by New Hope Fund and Haixi Pharmaceutical. The owner has organized two batches of partners to conduct site selection and on-site inspections, and
|
|
|
Total Investment:
|
5000 million yuan
|
|
|
Expected to Attract Investment:
|
5000 million yuan
|
|
|
Benefit Analysis:
|
none
|
|
|
Reason and Condition:
|
none
|
|
|
Content and Scale:
|
The planned land area is 300-500 acres, based on projects such as Xinchang Peptide Park, Hongbao Pharmaceutical and Machinery Industry Complex, Baihe Cold Chain Logistics Park, Baishukang Medical, Bopu Medical, and Aoyan Medical Supplies Production. With Xiuyu Medical and Health Industrial Park as the carrier, we will introduce high-end medical equipment, medical and nursing services, marine biotechnology, and other enterprises to deepen cooperation in the field of life and health between the two sides, and create a demonstration zone for cooperation in the life and health industry between the two sides of the Taiwan Strait.
|
|
|
Others:
|
none
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.